Business Context and Reporting Period
Envoy Medical, Inc. (Nasdaq: COCH, COCHW) filed this Form 8-K on February 23, 2026, reporting events occurring on February 23 and February 24, 2026. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding regulatory compliance and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material event reported is the resolution of a listing compliance issue. On February 23, 2026, the Company received confirmation from the Nasdaq Listing Qualifications Hearings office that it has evidenced compliance with Nasdaq Listing Rule 5550(b)(2), satisfying the requirements of a prior Hearing Panel letter dated October 23, 2025.
Outlook, Risks, and Management Commentary
While the Company has regained compliance, it remains subject to a discretionary panel monitor for a period of one year commencing February 12, 2026, pursuant to Nasdaq Listing Rule 5815(d)(4)(B). The Company issued a press release on February 24, 2026, confirming this status, which is incorporated by reference as Exhibit 99.1. No specific financial guidance or new risk factors were disclosed in this filing.
Investor Verification Checklist
- Verify the Company's continued compliance with Nasdaq listing standards during the one-year monitoring period.
- Review the attached press release (Exhibit 99.1) for additional details on the compliance resolution.
- Monitor future filings for the Company's next scheduled financial report to assess operational and financial health, as this 8-K contains no financial data.